The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
The study will run across 18 sites and enroll roughly 200 patients over 24 months
Patients with BRCA mutations often face aggressive disease and poor prognosis
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Subscribe To Our Newsletter & Stay Updated
